Skip to main content

Table 4 Changes in R0 resection rates after neoadjuvant therapy

From: The correlation between the margin of resection and prognosis in esophagogastric junction adenocarcinoma

Study

N

(AEG)

R0 resection rates

Surgery alone

NACT

NACRT

P value

FNCLCC [86]

168

73%

84%

 

0.04

MRC trial [87]

206

76.4%

75%

 

/

European Organisation [88]

144

66.7%

81.9%

 

0.036

Bosset study [89]

297

  

81%

/

Lee study [89, 90]

101

95%

 

100%

/

Cross trial [32]

275

69%

 

92%

 < 0.001

Burmeister’s study [91]

75

 

80.5%

84.6%

0.61

Nusrath’s study [92]

70

 

86%

88%

1

Germany trial [93]

126

 

69.5%

71.5%

/

  1. Adverse prognostic factors for advanced-stage SRC include the invasive SRC phenotype, a high risk of lymph node and peritoneal metastasis, adjacent organ involvement, differential response to neoadjuvant therapy, and a low R0 resection rate [96]